Health-related Quality of Life Measured by the Short Form 36 (SF-36) in Systemic Sclerosis: Correlations with Indexes of Disease Activity and Severity, Disability, and Depressive Symptoms

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2004 Aug 10

PMID 15300468

Citations 38

Authors

Elisabetta Danieli

Paolo Airo

Lorenzo Bettoni

Massimo Cinquini

Chiara M Antonioli

Ilaria Cavazzana

Franco Franceschini

Roberto Cattaneo

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to evaluate health-related quality of life (HR-QOL) in patients with systemic sclerosis (SSc), to compare it with that of patients with rheumatoid arthritis (RA), and to correlate it with other parameters. HR-QOL was evaluated by the Short Form 36 (SF-36), SSc disease activity and severity by preliminary indexes recently proposed, disability by the Health Assessment Questionnaire (HAQ), and depressive symptoms by the Beck Depression Inventory. HR-QOL perception was not statistically different in patients with SSc and RA, except that patients with diffuse cutaneous involvement had worse scores in the general health and mental health dimensions than patients with RA (p=0.03). Compared with RA, patients with SSc tended to perceive less bodily pain (p=0.06) and have less disability (p=0.04) but to report higher depressive symptom scores (p=0.05). SSc patients' HR-QOL was associated with some disease severity scales (general, kidney and, less significantly, heart), but it was poorly correlated with the other evaluated disease activity and severity indexes. A strong correlation with disability and with depressive symptoms was observed. In conclusion, patients with SSc perceived a reduced HR-QOL similar to that of patients with RA. SF-36 may provide useful information in their evaluation.

Citing Articles

Psychological impact of autologous hematopoietic stem cell transplantation in systemic sclerosis patients and influence of resilience.

Schmalzing M, Gernert M, Frohlich M, Henes J, Schwindl N, Zerhusen L Front Immunol. 2024; 15:1436639.

PMID: 39512343 PMC: 11540678. DOI: 10.3389/fimmu.2024.1436639.

Factors associated with physical function among people with systemic sclerosis: a SPIN cohort cross-sectional study.

Dal Santo T, Rice D, Carrier M, Virgili-Gervais G, Levis B, Kwakkenbos L Rheumatology (Oxford). 2024; 63(10):2660-2669.

PMID: 38471107 PMC: 11443018. DOI: 10.1093/rheumatology/keae162.

Characteristics of ScleroID highlighting musculoskeletal and internal organ implications in patients afflicted with systemic sclerosis.

Nagy G, Dobrota R, Becker M, Minier T, Varju C, Kumanovics G Arthritis Res Ther. 2023; 25(1):84.

PMID: 37210571 PMC: 10199621. DOI: 10.1186/s13075-023-03063-1.

Functional disability and health-related quality of life among systemic sclerosis patients in Bangladesh.

Hossain S, Choudhury M, Haque M, Yeasmin S, Hossain F, Zaman M BMC Rheumatol. 2022; 6(1):60.

PMID: 36175976 PMC: 9524111. DOI: 10.1186/s41927-022-00291-x.

The Preventive Role of Physical Activity in Systemic Sclerosis: A Cross-Sectional Study on the Correlation with Clinical Parameters and Disease Progression.

Antinozzi C, Grazioli E, De Santis M, Motta F, Sgro P, Mari F Int J Environ Res Public Health. 2022; 19(16).

PMID: 36011938 PMC: 9407825. DOI: 10.3390/ijerph191610303.

References

Hill C, Parsons J, Taylor A, Leach G . Health related quality of life in a population sample with arthritis. J Rheumatol. 1999; 26(9):2029-35. View

Bettoni L, Geri A, Airo P, Danieli E, Cavazzana I, Antonioli C . Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol. 2002; 21(3):244-50. DOI: 10.1007/pl00011223. View

Kvien T, Kaasa S, Smedstad L . Performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. II. A comparison of the SF-36 with disease-specific measures. J Clin Epidemiol. 1998; 51(11):1077-86. DOI: 10.1016/s0895-4356(98)00099-7. View

Benrud-Larson L, Haythornthwaite J, Heinberg L, Boling C, Reed J, White B . The impact of pain and symptoms of depression in scleroderma. Pain. 2002; 95(3):267-275. DOI: 10.1016/S0304-3959(01)00409-2. View

Medsger Jr T, Silman A, Steen V, Black C, Akesson A, Bacon P . A disease severity scale for systemic sclerosis: development and testing. J Rheumatol. 1999; 26(10):2159-67. View

van der Heijde D, van t Hof M, van Riel P, Theunisse L, Lubberts E, van Leeuwen M . Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990; 49(11):916-20. PMC: 1004262. DOI: 10.1136/ard.49.11.916. View

Da Costa D, Dobkin P, Fitzcharles M, Fortin P, Beaulieu A, Zummer M . Determinants of health status in fibromyalgia: a comparative study with systemic lupus erythematosus. J Rheumatol. 2000; 27(2):365-72. View

Steen V, Medsger Jr T . The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum. 1997; 40(11):1984-91. DOI: 10.1002/art.1780401110. View

. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23(5):581-90. DOI: 10.1002/art.1780230510. View

10.

Wiles N, SCOTT D, Barrett E, Merry P, Arie E, Gaffney K . Benchmarking: the five year outcome of rheumatoid arthritis assessed using a pain score, the Health Assessment Questionnaire, and the Short Form-36 (SF-36) in a community and a clinic based sample. Ann Rheum Dis. 2001; 60(10):956-61. PMC: 1753385. DOI: 10.1136/ard.60.10.956. View

11.

Roca R, Wigley F, White B . Depressive symptoms associated with scleroderma. Arthritis Rheum. 1996; 39(6):1035-40. DOI: 10.1002/art.1780390623. View

12.

Ware Jr J, Sherbourne C . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30(6):473-83. View

13.

Benrud-Larson L, Heinberg L, Boling C, Reed J, White B, Wigley F . Body image dissatisfaction among women with scleroderma: extent and relationship to psychosocial function. Health Psychol. 2003; 22(2):130-9. View

14.

Calkins D, Rubenstein L, Cleary P, Davies A, Jette A, Fink A . Failure of physicians to recognize functional disability in ambulatory patients. Ann Intern Med. 1991; 114(6):451-4. DOI: 10.7326/0003-4819-114-6-451. View

15.

Husted J, Gladman D, Farewell V, Cook R . Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001; 45(2):151-8. DOI: 10.1002/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T. View

16.

LeRoy E, Black C, FLEISCHMAJER R, Jablonska S, Krieg T, Medsger Jr T . Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15(2):202-5. View

17.

Merkel P, Herlyn K, Martin R, Anderson J, Mayes M, Bell P . Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum. 2002; 46(9):2410-20. DOI: 10.1002/art.10486. View

18.

McHorney C, Ware Jr J, Lu J, Sherbourne C . The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994; 32(1):40-66. DOI: 10.1097/00005650-199401000-00004. View

19.

Cossutta R, Zeni S, Soldi A, Colombelli P, Masserini A, Fantini F . [Evaluation of quality of life in patients with systemic sclerosis by administering the SF-36 questionnaire]. Reumatismo. 2002; 54(2):122-7. DOI: 10.4081/reumatismo.2002.122. View

20.

Clements P, Wong W, Hurwitz E, Furst D, Mayes M, White B . The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis Rheum. 2001; 44(3):653-61. DOI: 10.1002/1529-0131(200103)44:3<653::AID-ANR114>3.0.CO;2-Q. View